MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
January 4, 2005
Rich Smith
Blood for Sale Cord blood harvester ViaCell moves closer to its IPO, with pricing to be in the $7 to $9 range and will float 7.5 million shares, though still on a date "to be announced." mark for My Articles similar articles
The Motley Fool
August 2, 2006
Rich Smith
Foolish Forecast: Anemic ViaCell The cord blood storage specialist is due to report its second quarter 2006 numbers tomorrow. Investors, take note. mark for My Articles similar articles
The Motley Fool
November 8, 2005
Rich Smith
ViaCell Looks Healthier The cord blood collector reports narrowing losses. Investors, take note. mark for My Articles similar articles
The Motley Fool
September 20, 2005
Rich Smith
ViaCell's Cancer Trial Snag The cord blood collector suffers a research setback. Investors should keep in mind that the real money-maker behind ViaCell is its ViaCord cord blood storage business. mark for My Articles similar articles
The Motley Fool
February 23, 2007
Rich Smith
Foolish Forecast: ViaCell Doing Well? The cord blood specialist is set to report its fourth-quarter and full-year 2006 numbers shortly. Investors, here is what you can expect to see. mark for My Articles similar articles
The Motley Fool
January 25, 2005
Rich Smith
ViaCell's Costly Mistake Cord blood harvester neglects to collect the cash with an undervalued IPO. mark for My Articles similar articles
The Motley Fool
May 4, 2006
Rich Smith
ViaCell Looking Sickly As expected, the company remains solvent by virtue of one division: its ViaCord umbilical cord blood storage unit, which provided $11.9 million of the quarter's $12.1 million in revenues. But even that good news fails to outweigh the bad news. Investors, take note. mark for My Articles similar articles
The Motley Fool
April 18, 2005
Rich Smith
U.S. Government Out for Blood Two companies await as the Institute of Medicine advocates improvements in cord blood banking. Newly public ViaCell has been plummeting along with rival Cryo-Cell, down roughly 40% over the past three months. mark for My Articles similar articles
The Motley Fool
April 27, 2007
Rich Smith
Foolish Forecast: ViaCell Doing Swell? The cord blood specialist is set to release its first-quarter 2007 earnings. Investors, here is what you can expect to see. mark for My Articles similar articles
The Motley Fool
August 13, 2007
Rich Smith
ViaCell Sees the Light Despite rising sales at its trademark ViaCord umbilical cord blood storage service, and gross margin from this service rising in tandem, the firm's operating and net results remain mired in thick red ink. Investors, take note. mark for My Articles similar articles
The Motley Fool
October 2, 2007
Brian Orelli
PerkinElmer and ViaCell: A Bloody Good Deal? PerkinElmer buys umbilical cord storage company ViaCell for $300 million. Investors, take note; the merger may be a good fit for both companies. mark for My Articles similar articles
The Motley Fool
August 8, 2007
Rich Smith
Foolish Forecast: Watch for ViaCell to Tip Its Hand Will second-quarter results from cord-blood storage specialist ViaCell meet or exceed the relatively low management expectations? And will the next quarter improve, as the company has previously predicted? mark for My Articles similar articles
The Motley Fool
August 8, 2006
Rich Smith
Second Opinion on ViaCell The prognosis isn't good. Is there still hope for ViaCell? Of course! Hope springs eternal. If ViaCell can just tighten its purse strings, investors may yet find a way to save blood and make money. mark for My Articles similar articles
The Motley Fool
May 1, 2007
Rich Smith
The Losses Swell at ViaCell Given that ViaCell has been ramping up its sales and marketing spending for about a year, it's about time ViaCell's stock start showing some results from this "investment." mark for My Articles similar articles
The Motley Fool
April 3, 2006
Seth Jayson
No Stemming the Flow of Shares Another year, another large dollop of shares to water down the juice at StemCells. This company excels at burning money, as its cash flow statements show. Invest accordingly. mark for My Articles similar articles
The Motley Fool
March 5, 2007
Rich Smith
ViaCell Not Doing Well The company's biotech half continues to sap revenue from the moneymaking side. Investors, take note. mark for My Articles similar articles
The Motley Fool
November 30, 2004
Rich Smith
Breaking Rules and Saving Lives Cord blood offers an ethical means of using stem cells to heal illness. While two top companies in the field are private, over the counter traded Cryo-Cell lost as much money as it collected in revenues last year. mark for My Articles similar articles
The Motley Fool
December 29, 2005
Rich Smith
New Year's 2016: Four Fabulous Fads Today's passing fads are tomorrow's market dominators. Investing is already more art than science, and investing for 10 years in the future -- even more so. mark for My Articles similar articles
The Motley Fool
February 26, 2007
Rich Smith
Foolish Forecast: Cryo-Cell Defrosting The cord-blood storage specialist will report its fourth-quarter and full-year financial news shortly. Investors, here is what you can expect to see. mark for My Articles similar articles
The Motley Fool
May 23, 2006
Anders Bylund
Foolish Forecast: TiVo The original purveyor of digital video recorders is set to release earnings news for first-quarter 2007 tomorrow. Should investors expect great things or a humdrum quarter? mark for My Articles similar articles
BusinessWeek
June 27, 2005
Arlene Weintraub
Stem Cells To Go ViaCell's goal is to mass-produce stem cells from umbilical cord blood. mark for My Articles similar articles